Tienda Elsevier

¿Aún no está registrado?

Información relevante

Consulte los artículos y contenidos publicados en éste medio, además de los e-sumarios de las revistas científicas en el mismo momento de publicación

Máxima actualización

Esté informado en todo momento gracias a las alertas y novedades

Promociones exclusivas

Acceda a promociones exclusivas en suscripciones, lanzamientos y cursos acreditados

Crear Mi cuenta

* = Required fields

Enter your email address

User name *

Annals of Hepatology

Annals of Hepatology Most often read

Annals of Hepatology

ISSN: 1665-2681

Annals of Hepatology (AoH) is an international, open access journal published bi-monthly with funds from the Fundación Clínica Médica Sur. It is the official journal of the Mexican Association of Hepatology (AMH), the Latin American Association for the Study of the Liver (ALEH), the Canadian Association for the Study of the Liver (CASL) and the Czech Society of Hepatology (CSH). AoH publishes editorials, opinions, concise reviews, original articles, brief reports, letters to the editor, news from affiliated associations, clinical practice guidelines and summaries of congresses in the field of Hepatology.

Topics covered by AoH include alcoholic liver disease, autoimmune hepatitis, biliary diseases, drug-induced liver injury, genetic liver diseases, NAFLD/NASH and viral hepatitis (HAV, HBV, HCV, HDV, HEV). Our journal seeks to publish articles on basic clinical care and translational research focused on preventing rather than treating the complications of end-stage liver disease.

See more Open Access Option

Indexed in:

Scopus, Medline, Directory of Open Access Journals (DOAJ), Science Citation Index Expanded (SCIE), SCImago Journal Rank (SJR), SNIP

See more

Follow us:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2025

See more

Impact factor 2024

4.4

Citescore

CiteScore measures average citations received per document published.

See more

Citescore 2024

9.1

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

See more

SJR 2024

1.011

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

See more

SNIP 2024

1.057

View more metrics

Journal Information

Most often read

Vol. 31. Issue. 1

2365

First Latin American consensus on the treatment and prophylaxis of hepatic encephalopathy

Fátima Higuera-de-la-Tijera, Mario Reis Alvares-da-Silva, Graciela Elia Castro-Narro, Josué Barahona-Garrido, Enrique Carrera-Estupiñán, Jorge Garavito-Rentería, Héctor Adolfo Henríquez-Meléndez, Geovanny Hernández-Cely, ... José Antonio Velarde-Ruiz Velasco

Ann Hepatol. 2026;31:102142

2365

Full text access

Share

2243

Real-world BCLC adherence and survival in hepatocellular carcinoma: first prospective study from Central America

Pablo Coste Murillo, María Fernanda Lynch-Mejía, Wagner Ramírez Quesada, Francisco Vargas Navarro, Vanessa López Jara, Silvia Alfaro Cartín, Ariela Gómez Pérez, Sheila Araya Chavarría, ... Karen Melissa Rodríguez Masís

Ann Hepatol. 2026;31:102154

2243

Full text access

Share

2118

Comparisons of global incidence and risk factor profiles of hepatocellular carcinoma and intrahepatic cholangiocarcinoma

Tianhao Wu, Mingyi Du, Tiejun Zhang, Xingdong Chen, Zhenqiu Liu

Ann Hepatol. 2026;31:102139

2118

Full text access

Share

1764

Noninvasive elastography-based assessment of liver fibrosis in primary biliary cholangitis

Xiaohui Ye, Lingling He, Caihong Deng, Junru Yang, Ping Li, Hongshan Wei

Ann Hepatol. 2026;31:102150

1764

Full text access

Share

1703

Diagnosis of metabolic dysfunction-associated steatotic liver disease by triglyceride glucose-body mass index: A systematic review and meta-analysis

Kexin Du, Yafang Huang, Yanhui Yu, Jianrong Guo, Jianmei Feng, Feng Jiang

Ann Hepatol. 2026;31:102122

1703

Full text access

Share

1370

Pruritus in primary biliary cholangitis: insights from the German PBC registry across secondary and tertiary care

Toni Herta, Annegret Franke, Tobias Müller, Kerstin Stein, Heike Bantel, Rainer Günther, Gerald Denk, Philipp A. Reuken, ... Andreas E. Kremer

Ann Hepatol. 2026;31:102140

1370

Full text access

Share

1273

Prospective surveillance reveals high rates of antimicrobial resistance in urinary tract infections among patients with cirrhosis.

Carolina Vazquez, Gonzalo Gómez Perdiguero, Esteban González Ballerga, Ilse Pardo Ivirico, Camila M. Briz, Agustín Di Santo, Maria D. Murga, Ana Palazzo, ... Sebastián Marciano

Ann Hepatol. 2026;31:102135

1273

Full text access

Share

1222

Incidence and predictors of non-hepatic cancers in biopsy-proven alcohol-related liver disease

Mayur Brahmania, Zaid Hindi, Nancy Shi, Juan Pablo Arab, Neil Rajoriya, Guruprasad P. Aithal, Michael Allison, Hannes Hagström, ... WALDO investigators

Ann Hepatol. 2026;31:101908

1222

Full text access

Share

1200

Epidemiology and etiologic trends of hepatocellular carcinoma in cirrhotic patients in Mexico: a multicenter retrospective study (2018–2024)

Nahum Méndez-Sánchez, Mariana M. Ramírez-Mejía, Carlos Cortez-Hernández, Elianee M. Tovar-Bojorquez, Raúl Contreras-Omaña, Juan D. Monsiváis-Morales, Jacqueline Cordova-Gallardo, Mauricio Castillo-Barradas, ... Heriberto Rodríguez-Hernández

Ann Hepatol. 2026;31:102131

1200

Full text access

Share

1198

Reevaluating the clinical course of AMA-positive patients with normal liver enzymes: A large retrospective cohort study

Ahmad Yahia, Fadi Abu Baker, Mifleh Tatour, Rawi Hazzan

Ann Hepatol. 2026;31:102147

1198

Full text access

Share

1161

Long-term albumin treatment for decompensated cirrhosis in Italy: A propensity score-matched, retrospective, real-world chart analysis

Wim Laleman, Jonel Trebicka, Alastair O’Brien, Giacomo Zaccherini, Paolo Caraceni, Joana F. Rodrigues, Xiang Zhang, Maebh Kelly, ... Paolo Angeli

Ann Hepatol. 2026;31:102153

1161

Full text access

Share

1121

Alpha-1 antitrypsin Pi*MZ variant increases the risk of liver disease progression in MASLD and MASH

Bradley Jermy, Jack Brownrigg, Pavel Strnad, Rohit Loomba

Ann Hepatol. 2026;31:102143

1121

Full text access

Share

1034

Bidirectional association between chronic liver disease and chronic kidney disease: a longitudinal study based on CHARLS 2011–2020 data

Yuan He, Fan Zhang, Zixuan Zhang, Xianwen Zhang, Yifei Zhong

Ann Hepatol. 2026;31:102115

1034

Full text access

Share

1029

Limitations of MELD and MELD 3.0 for prognostication in patients with cirrhosis hospitalized with acute decompensation: an analysis of the ATTIRE trial

Nikolaj Torp, Nick Freemantle, Mads Israelsen, Aleksander Krag, Alastair O’Brien

Ann Hepatol. 2026;31:102137

1029

Full text access

Share

966

Effects of artificial liver support systems on nosocomial infections and mortality in non-transplanted liver failure patients

Yuan Li, Xiaoting Wang, Junkai Fan, Jiale Xie, Huimin Liu, Chunrong Ping, Zhijie Feng, Yan Wang

Ann Hepatol. 2026;31:102113

966

Full text access

Share

953

Assessment of metabolic dysfunction-associated steatotic liver disease, alcohol-associated liver disease, and metabolic dysfunction and alcohol-associated steatotic liver disease in open Mexican population

Jorge Emilio Lira-Vera, Ángel Daniel Santana-Vargas, Gabriela Gutiérrez-Reyes, Oscar Morales-Gutiérrez, María de Fátima Higuera-de la Tijera, Diana Montemira-Orozco, Christian Hinojosa-Segura, Moisés Martínez-Castillo, ... José Luis Pérez-Hernández

Ann Hepatol. 2026;31:102149

953

Full text access

Share

899

Prognosis of hepatocellular carcinoma in the French overseas territories and comparison with a tertiary center in mainland France

Alolia Aboikoni, Manon Allaire, Dominique Louvel, Marthe Alogo A. Nwatsok, Paul Ngock Dime, Ala Ouni, Larissa Tangan, Magaly Zappa, ... Moana Gelu-Simeon

Ann Hepatol. 2026;31:102120

899

Full text access

Share

853

Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab

Lorenz Kocheise, Jan Kempski, Yunhe Tang, Lorenz Balcar, Victoria Berger, Miriam Tomczak, Joao Gorgulho, Ramsha Masood, ... Kornelius Schulze

Ann Hepatol. 2026;31:102138

853

Full text access

Share

834

Aspartate aminotransferase‑to‑platelet ratio index (APRI) reliably excludes advanced fibrosis and cirrhosis in treated autoimmune hepatitis

Martine A.M.C. Baven-Pronk, Camiel J.M. Marijnissen, Maaike Biewenga, Albert F. Stättermayer, Maarten E. Tushuizen, Bart van Hoek

Ann Hepatol. 2026;31:102146

834

Full text access

Share

816

Trends and health inequalities of hepatitis virus-associated liver cancer mortality during 1990–2050

Yujiao Deng, Jingyue Tan, Jian Zu, Zixuan Xing, Zhanpeng Yang, Yue Zhang, Yajing Bo, Xu Gao, ... Yang Yang

Ann Hepatol. 2026;31:102144

816

Full text access

Share

Article options

Tools